Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC) Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Rugo, H. S., Brown-Glaberman, U., Yardley, D. A., Kim, S., de Boer, M., Nowecki, Z., Glavicic, V., Wolf, I., Claes, N., Sohn, J., Bachelot, T., Kaufman, P. A., Baughman, J., Hong, S., Jacobs, K., Rock, E., Gradishar, W. J. AMER ASSOC CANCER RESEARCH. 2021
View details for Web of Science ID 000618737700274